Dostarlimab

CHEBI:CHEBI_752713

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

generic_name
Dostarlimab
rxcui
2539977
product_type
DRUG FOR FURTHER PROCESSING
listing_expiration_date
20251231
dosage_form
INJECTION, SOLUTION
marketing_start_date
20210422
package_marketing_start_date
22-APR-21
route
INTRAVENOUS
active_ingredient_strength
50 g/L
marketing_category
DRUG FOR FURTHER PROCESSING
labeler_name
WuXi Biologics Co., Ltd.
manufacturer_name
GlaxoSmithKline LLC
nui
N0000191259
pharm_class_epc
Programmed Death Receptor-1 Blocking Antibody [EPC]
pharm_class
Programmed Death Receptor-1-directed Antibody Interactions [MoA]
pharm_class_moa
Programmed Death Receptor-1-directed Antibody Interactions [MoA]
product_ndc
0173-0898
spl_id
a0c3423e-b2e8-43f1-b9b3-45d7dd734dde
active_ingredient_name
DOSTARLIMAB
package_ndc
0173-0898-03
package_description
1 VIAL in 1 CARTON (0173-0898-03) / 10 mL in 1 VIAL
brand_name
Jemperli
brand_name_base
Jemperli
application_number
BLA761174
unii
P0GVQ9A4S5
spl_set_id
095eab9f-545a-4f12-bfb7-19477fb901a5
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class